PF-04136309

a CCR2 inhibitor

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Febrile Neutropenia 01/01/2016 - "Grade 3 or higher adverse events reported in at least 10% of the patients receiving PF-04136309 included neutropenia (n=27), febrile neutropenia (n=7), lymphopenia (n=4), diarrhoea (n=6), and hypokalaemia (n=7). "
2.	Neutropenia 01/01/2016 - "Grade 3 or higher adverse events reported in at least 10% of the patients receiving PF-04136309 included neutropenia (n=27), febrile neutropenia (n=7), lymphopenia (n=4), diarrhoea (n=6), and hypokalaemia (n=7). "
3.	Neoplasm Metastasis (Metastasis) 01/01/2021 - "PF-04136309, a small molecule and specific inhibitor of CCR2 can largely suppressed GOLM1-mediated CRC metastasis. "
4.	Lymphopenia (Lymphocytopenia) 01/01/2016 - "Grade 3 or higher adverse events reported in at least 10% of the patients receiving PF-04136309 included neutropenia (n=27), febrile neutropenia (n=7), lymphopenia (n=4), diarrhoea (n=6), and hypokalaemia (n=7). "